

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 November 2009 (12.11.2009)(10) International Publication Number
WO 2009/136995 A2

(51) International Patent Classification:

C07D 239/48 (2006.01) A61P 35/00 (2006.01)
 C07D 401/12 (2006.01) A61P 9/00 (2006.01)
 C07D 403/12 (2006.01) A61K 31/506 (2006.01)
 C07D 413/12 (2006.01) C07D 407/12 (2006.01)
 C07D 417/12 (2006.01) C07D 409/12 (2006.01)

(21) International Application Number:

PCT/US2009/002401

(22) International Filing Date:

16 April 2009 (16.04.2009)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/045,406	16 April 2008 (16.04.2008)	US
61/045,499	16 April 2008 (16.04.2008)	US
61/120,346	5 December 2008 (05.12.2008)	US
61/120,348	5 December 2008 (05.12.2008)	US

(71) Applicant (for all designated States except US):

POR-TOLA PHARMACEUTICALS, INC. [US/US]; 270 E. Grand Avenue, Suite 22, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) **Inventors/Applicants (for US only):** **JIA, Zhaozhong, J.** [US/US]; 1576e Marina Court, San Mateo, CA 94403 (US). **VENKATARAMANI, Chandrasekar** [IN/US]; 1 Chart Lane, Redwood City, CA 94065 (US). **HUANG, Wolin** [US/US]; 872 Arcturus Circle, Foster City, CA 94404 (US). **MEHROTRA, Mukund** [US/US]; 464 Miller Avenue, Apt. #12, South San Francisco, CA 94080

(US). **SONG, Yonghong** [US/US]; 860 Polaris Avenue, Foster City, CA 94404 (US). **XU, Qing** [CN/US]; 968 Diaz Lane, Foster City, CA 94404 (US). **BAUER, Shawn, M.** [US/US]; 181 Beachview Avenue, Pacifica, CA 94044 (US). **PANDEY, Anjali** [US/US]; 4506 Amiens Avenue, Fremont, CA 94555 (US).

(74) **Agents:** **HOPKINS, Mark, H., D.** et al.; Townsend And Townsend And Crew LLP, Two Embarcadero Street, Eighth Floor, San Francisco, CA 94111-3834 (US).


(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: INHIBITORS OF SYK PROTEIN KINASE

FIG. 1.



(57) **Abstract:** The present invention is directed to compounds of formula I-V and tattooers thereof or pharmaceutically acceptable salts, esters, and pro drugs thereof which are inhibitors of sky kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.



Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*